MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation
Open Access
- 1 July 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Neuro-Oncology
- Vol. 101 (3), 405-417
- https://doi.org/10.1007/s11060-010-0274-x
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- O6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implicationsNeuro-Oncology, 2010
- Prognostic significance of loss of O6-methylguanine-DNA methyltransferase expression in supratentorial diffuse low-grade astrocytomaSurgical Neurology, 2007
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Genetic Pathways to Primary and Secondary GlioblastomaThe American Journal of Pathology, 2007
- O6-methylguanine-DNA methyltransferase methylation andTP53 mutation in malignant astrocytomas and their relationships with clinical courseInternational Journal of Cancer, 2004
- Hypermethylation of the DNA repair gene MGMT: association with TP53 G:C to A:T transitions in a series of 469 nervous system tumorsMutation Research - Reviews in Mutation Research, 2004
- Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytomaCancer, 2004
- MGMT: its role in cancer aetiology and cancer therapeuticsNature Reviews Cancer, 2004
- Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with TemozolomideClinical Cancer Research, 2004
- Determination of the Molecular Relationship Between Multiple Tumors Within One Patient Is of Clinical ImportanceJournal of Clinical Oncology, 2002